Riferimento farmaci
Ponesimod
Ponesimod is a medicine in the class central nervous system. It is used for multiple sclerosis.
- Classe del farmaco: Central Nervous System
- Indicato per: multiple sclerosis
Ultimo aggiornamento
Per operatori sanitari — solo a scopo di riferimento. Questa pagina è una sintesi breve, non è un parere medico e non sostituisce il RCP ufficiale né il giudizio clinico. Verificare sempre prima di prescrivere o dispensare.
Il contenuto clinico di questa pagina è disponibile solo in inglese.
In breve
- Classe del farmaco
- Central Nervous System
- Codice ATC
- L04AE04
- Forme farmaceutiche comuni
- compressa
- Dosaggi comuni
- 20 mg, 2 mg, 10 mg
- Interazioni note
- 127 (Controindicata: 2 · Maggiore: 46 · Moderata: 71 · Minore: 8)
- Nomi commerciali
- 5
- Paesi e mercati
- 4
Per cosa si usa
Come agisce
Sphingosine 1-phosphate (S1P) receptor 1 modulator that binds with high affinity to S1P receptor 1
Dose abituale nell'adulto (sintesi del foglio illustrativo)
Multiple Sclerosis (Initiation) Starter pack must be used for initiating treatment: 2 mg PO qDay initially; increase dose as per dose titration regimen (14-day titration)
Gravidanza e allattamento
- Gravidanza
- Unsafe EU label: contraindicated in pregnancy. In rats and rabbits it caused fetal death and malformations at clinical exposures without maternal toxicity (S1P receptor role in embryo development); another S1P modulator raised birth-defect risk in humans. Use contraception; stop 1 week before conceiving.
- Allattamento
- Unsafe No human milk data; rat offspring were exposed via milk. US label: weigh benefits; EU label: risk cannot be excluded, should not be used while breastfeeding. LactMed: long half-life and possible infant toxicity; experts advise avoiding the related fingolimod.
Effetti indesiderati segnalati
- Somnolence
- Elevated hepatic transaminases
- Hypertension
- Urinary tract infection
- Dyspnea
- Dizziness
Controindicazioni
- Presence of Mobitz type II second-degree, third-degree AV block, or sick sinus syndrome, unless patient has functioning pacemaker
- In the past 6 months, experienced myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure (HF) requiring hospitalization, or Class III/IV HF
Chi deve prestare attenzione
- Consider possibility of severe exacerbation of disease after discontinuing therapy; monitor for severe increase in disability upon discontinuation and appropriately treat; after stopping therapy in the setting of PML, monitor for development of immune reconstitution inflammatory syndrome (PML-IRIS)
- Elevated transaminases may occur; if symptoms (eg, unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, rash with eosinophilia, jaundice, dark urine) occur during therapy, check hepatic enzymes; if significant liver injury confirmed, discontinue therapy
Informare il farmacista o il medico di gravidanza o allattamento, malattie renali o epatiche, allergie e di ogni altro farmaco o integratore assunto.
Interazioni principali (127)
- Fingolimod + Ponesimod Contraindicated
- Ponesimod + Siponimod Contraindicated
- Amiodarone + Ponesimod Major
- Amisulpride + Ponesimod Major
- Anagrelide + Ponesimod Major
- Anti-thymocyte + Ponesimod Major
- Asenapine + Ponesimod Major
- Atenolol + Ponesimod Major
- Atenolol-chlorthalidone + Ponesimod Major
- Betaxolol + Ponesimod Major
Per gli utenti Pro+
Sblocca la pagina completa
Crei un account e avvii una prova di Pro+ per aprire la monografia completa di Ponesimod: dosi, gravidanza e allattamento, effetti indesiderati, avvertenze e tutte le interazioni.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Paediatric dosing
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
Provi Pro+ gratis per 14 giorni sul web. Nessuna carta.
Altri farmaci della stessa classe
Domande frequenti
What is Ponesimod used for?
Ponesimod is a medicine in the class central nervous system. It is used for Multiple sclerosis.
What side effects have been reported with Ponesimod?
Somnolence, Elevated hepatic transaminases, Hypertension, Urinary tract infection, Dyspnea, Dizziness.
Can Ponesimod be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. EU label: contraindicated in pregnancy. In rats and rabbits it caused fetal death and malformations at clinical exposures without maternal toxicity (S1P receptor role in embryo development); another S1P modulator raised birth-defect risk in humans. Use contraception; stop 1 week before conceiving. Breastfeeding: Unsafe. No human milk data; rat offspring were exposed via milk. US label: weigh benefits; EU label: risk cannot be excluded, should not be used while breastfeeding. LactMed: long half-life and possible infant toxicity; experts advise avoiding the related fingolimod.
What does Ponesimod interact with?
MediHelp lists 127 known interactions for Ponesimod. Contraindicated: 2 · Major: 46 · Moderate: 71 · Minor: 8. The most serious include Fingolimod, Siponimod, Amiodarone.
Monografie complete, posologie e verifica delle interazioni nell'app MediHelp
Apra il riferimento completo, verifichi le interazioni tra più farmaci e usi gli strumenti di posologia nell'app MediHelp.
